 | • レポートコード：MRC2203A391 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の涙嚢炎市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（急性、慢性、その他）分析、流通チャネル別（機関販売、小売販売）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の涙嚢炎市場規模：疾患別（急性、慢性、その他） ・世界の涙嚢炎市場規模：流通チャネル別（機関販売、小売販売） ・世界の涙嚢炎市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Aurobindo Pharma、Bess Medizintechnik GmbH、FCI Ophthalmics、…） ・市場機会・将来傾向 |
The dacryocystitis market studied is anticipated to register a CAGR of nearly 4.2%, during the forecast period.
· Certain factors that are driving the market growth include a rise in the prevalence of eye infections and increasing clinical research and subsequent new product launches.
· Dacryoadenitis is an inflammation of the lacrimal gland. Infections are rare and may be acute or chronic. Patients with acute dacryoadenitis suffer from a tender area of erythema and swelling in the lateral part of the upper lid. It may lead to preseptal or orbital cellulitis or may suppurate into an abscess.
· As per the study titled “Fungal infections of the eye”, fungal dacryocystitis accounts for approximately 5% of all acquired dacryocystitis and around 14% of cases of congenital dacryocystitis. Women are affected more frequently with all forms of dacryocystitis than men, probably because of anatomically narrower nasolacrimal ducts. It mostly affects individuals in their 50s or 60s.
Key Market Trends
Acute Dacryocystitis Holds Significant Share in the Dacryocystitis Market
Dacryocystitis can be acute or chronic and congenital or acquired. Symptoms of acute dacryocystitis start suddenly and often include fever and pus from the eye. Bacterial infections are usually the cause of acute dacryocystitis, and antibiotic treatment usually resolves the infection within a few days. People with acute dacryocystitis often experience more severe symptoms than those with chronic dacryocystitis. However, in all age groups, acute dacryocystitis generally resolves quickly after taking oral antibiotics.
North America Dominates the Dacryocystitis Market
The United States has witnessed a considerable rise in the number of dacryocystitis patients. According to the 2019 study (Grant D Gilliland et al), in adults, females are afflicted more commonly by dacryocystitis. Most studies demonstrate that 70-83% of cases of dacryocystitis occur in females. Congenital dacryocystitis occurs with equal frequency in both sexes. Moreover, the ease in the US government’s regulations and the availability of funds from various organizations, like the National Institute of Health, have provided the potential for researchers to invest more in drug discovery for the disease.
Competitive Landscape
The dacryocystitis market is competitive and consists of a few major players. Companies like Aurobindo Pharma, Bess Medizintechnik GmbH, FCI Ophthalmics, Glaxosmithkline PLC, Kaneka Corporation, Mylan NV, Nosch, Orex Pharma Pvt Ltd, and Pfizer Inc., hold the substantial share in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Prevalence of Eye Infections
4.2.2 Increasing Clinical Research and Subsequent New Product Launches
4.3 Market Restraints
4.3.1 Less Patient Awareness Regarding Various Treatment Procedures
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Indication
5.1.1 Acute
5.1.2 Chronic
5.1.3 Other Indications
5.2 By Distribution Channel
5.2.1 Institutional Sales
5.2.2 Retail Sales
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Aurobindo Pharma
6.1.2 Bess Medizintechnik GmbH
6.1.3 FCI Ophthalmics
6.1.4 Glaxosmithkline PLC
6.1.5 Kaneka Corporation
6.1.6 Mylan NV
6.1.7 Nosch
6.1.8 Orex Pharma Pvt Ltd
6.1.9 Pfizer Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS